Hipofosfatemia en nutrición parenteral: prevención y factores de riesgo asociados / Hypophosphatemia in parenteral nutrition: prevention and associated risks factors

Objetivo: Determinar la incidencia de hipofosfatemia en pacientes con nutrición parenteral, la cantidad de fosfato necesaria para prevenir esta complicación y los factores de riesgo asociados. Ámbito: Estudio observacional no controlado en un hospital de nivel III. Pacientes: pacientes ingresados con nutrición parenteral a los que se les ha realizado como mínimo una analitica completa. Intervención: Se registran durante un año, los días de nutrición parenteral, el fosfato administrado y los niveles plasmáticos de calcio ionizado, -glutamiltranspeptidasa, glucosa, fosfato, prealbúmina, urea y leucocitos. Para el análisis se aplica una regresión múltiple stepwise y una regresión logistica. Resultados: Se incluyeron en el estudio 827 determinaciones correspondientes a 401 pacientes. Las variables significativas (p < 0,05) fueron: fosfato administrado y los niveles séricos de calcio ionizado, glucosa, prealbúmina y urea; los coeficientes de regresión fueron 0,004 (95 por ciento IC: 0,002-0,006), -0,156 (95 por ciento IC: -0,270-0,037), 0,014 (95 por ciento IC: -0,022-0,009), 0,005 (95 por ciento CI: 0,0020,009) y 0,019 (95 por ciento IC: 0,016-0,022) respectivamente; la constante fue 1,0735 (95 por ciento IC: 0,939-1,2079). El riesgo de desarrollar hipofosfatemia disminuyó de 0,65 (95 por ciento IC: 0,33-1,26) a 0,16 (95 por ciento IC: 0,078-0.35) cuando el fosfato administrado variaba deL rango 7,5-17,5 mmol a valores superiores a 27,5 mmol. Conclusiones: es necesario suplementar rutinariamente las nutriciones con fosfato debido a que su contenido en las emulsiones lipídicas comercializadas no es suficiente para evitar la hipofosfatemia en la mayoría de pacientes con nutrición parenteral. El aporte de fosfato debe ser suficiente para restaurar el déficit de fosfato intracelular y compensar la caída de fosfato plasmático, con especial cuidado para los pacientes desnutridos, hiperglucémicos o con insuficiencia renal. Aportes de fosfato entre 27-37 mmol, disminuyen drásticamente la incidencia de hipofosfatemia en los pacientes estudiados, no registrándose ningún caso de hipofosfatemia severa (AU)

Aim: To determine the incidence of hypophosphatemia in parenterally fed patients, the phosphate amount necessary to prevent this complication and associated risks factors. Setting: Observational study, not controlled, in a third level hospital. Patients: In-patients with parenteral nutrition with at least a complete laboratory work-up. Intervention: For a complete year, days on parenteral nutrition, administered phosphate and plasmatic ionised calcium levels, γ-glutamiltranspeptidase, glucose, phosphate, pre-albumin, urea, and leukocytes were recorded. A multiple stepwise regression analysis and logistic regression are used for data analysis. Results: Eight hundred and twenty seven determinations, corresponding to 401 patients, were included. Significant variables (p < 0.05) were: administered phosphate and ionised calcium serum levels, glucose, pre-albumin, and urea; regression coefficients were 0.004 (95%CI: 0.002 to 0.006), -0.156 (95%CI: -0.270 to 0.037), -0.014 (95%IC: -0.022 to 0.009), 0.005 (95%CI: 0.002 to 0.009) and 0.019 (95%CI: 0.016 to 0.022), respectively; the constant was 1.0735 (95%CI: 0.939 to 1.2079). The risk for developing hypophosphatemia decreased from 0.65 (95%CI: 0.33 to 1.26) to 0.16 (95%CI: 0.078 to 0.35) when administered phosphate varied from the span 7.5-17.5 mmol to values higher than 27.5 mmol. Conclusions: It is necessary to routinely supplement nutrition with phosphate since its content in commercially available lipidic emulsions is not sufficient to prevent hypophosphatemia in the majority of patients with parenteral nutrition. Phosphate intake must be sufficient to restore the intracellular phosphate deficit and to compensate for the plasmatic phosphate fall, with special attention to poorly nourished, hyperglycaemic or with renal failure patients. Phosphate intakes around 27-37 mmol dramatically decrease the incidence of hypophosphatemia in studied patients, with no recorded cases of severe hypophosphatemia (AU)

[Hypophosphatemia in parenteral nutrition: prevention and associated risks factors]. / Hipofosfatemia en nutrición parenteral: prevención y factores de riesgo asociados.

AIM: To determine the incidence of hypophosphatemia in parenterally fed patients, the phosphate amount necessary to prevent this complication and associated risks factors. SETTING: Observational study, not controlled, in a third level hospital. PATIENTS: In-patients with parenteral nutrition with at least a complete laboratory work-up. INTERVENTION: For a complete year, days on parenteral nutrition, administered phosphate and plasmatic ionised calcium levels, y-glutamiltranspeptidase, glucose, phosphate, pre-albumin, urea, and leukocytes were recorded. A multiple stepwise regression analysis and logistic regression are used for data analysis. RESULTS: Eight hundred and twenty seven determinations, corresponding to 401 patients, were included. Significant variables (p < 0.05) were: administered phosphate and ionised calcium serum levels, glucose, pre-albumin, and urea; regression coefficients were 0.004 (95%CI: 0.002 to 0.006), -0.156 (95%CI: -0.270 to 0.037), -0.014 (95%IC: -0.022 to 0.009), 0.005 (95%CI: 0.002 to 0.009) and 0.019 (95%CI: 0.016 to 0.022), respectively; the constant was 1.0735 (95%CI: 0.939 to 1.2079). The risk for developing hypophosphatemia decreased from 0.65 (95%CI: 0.33 to 1.26) to 0.16 (95%CI: 0.078 to 0.35) when administered phosphate varied from the span 7.5-17.5 mmol to values higher than 27.5 mmol. CONCLUSIONS: It is necessary to routinely supplement nutrition with phosphate since its content in commercially available lipidic emulsions is not sufficient to prevent hypophosphatemia in the majority of patients with parenteral nutrition. Phosphate intake must be sufficient to restore the intracellular phosphate deficit and to compensate for the plasmatic phosphate fall, with special attention to poorly nourished, hyperglycaemic or with renal failure patients. Phosphate intakes around 27-37 mmol dramatically decrease the incidence of hypophosphatemia in studied patients, with no recorded cases of severe hypophosphatemia.

[A practical nursing guide for the planning and evaluation of the care of the patient with domiciliary parenteral nutrition. The planning of patient care with DPN]. / Guía práctica de enfermería para la planificación y evaluación de los cuidados del paciente con nutrición parenteral domiciliaria. Planificación de cuidados del paciente con NPD.

We present a proposal for the planning of nursing care for the patient with home parenteral nutrition (HPN). In this proposal the problems, goals, and actions to be taken by the nurse are defined. In this working guide, it is explained what the diverse aspects are that the nurse taking care of a patient with HPN needs to know, as well as the care to be given and the evaluation of the same, in order to insure that the patient with HPN is given a good preparation in his self-care, giving the patient an acceptable degree of independence and quality of life, as well as a lower risk of complications.

[Description of the computer program used at the Hospital de Bellvitge for monitoring and control in the Parenteral Nutrition Unit]. / Descripción del programa informático utilizado en el Hospital de Bellvitge para el seguimiento y control de la Unidad de Nutrición Parenteral.

The purpose of this paper is to introduce a computer program to control the Pharmacy Service Parenteral Nutrition Unit. The program's main feature is a broad menu of possibilities for the clinical monitoring of patients receiving PN. We explain its operation, potential and applications and give some practical examples of some of those applications.